Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioArctic ABBRCTF 80 5-Year Yield-on-Cost % is 0.67 as of Jul. 26, 2026, which is 68% below its 10-year median of 2.10. GuruFocus rates BRCTF with a GF Score™ of 80/100 and a GF Value™ of $49.29 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 150 Biotechnology companies, BioArctic AB ranks worse than 78% on this metric.
BioArctic AB's yield on cost for the quarter that ended in Mar. 2026 was 0.67.
The historical rank and industry rank for BioArctic AB's 5-Year Yield-on-Cost % or its related term are showing as below:
BRCTF'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.67 Med: 2.1 Max: 2.91
Current: 0.67
During the past 11 years, BioArctic AB's highest Yield on Cost was 2.91. The lowest was 0.67. And the median was 2.10.
BRCTF's 5-Year Yield-on-Cost % is ranked worse than 78% of 150
companies
in the Biotechnology industry
Industry Median: 1.695
vs BRCTF: 0.67
BioArctic AB (OTCPK:BRCTF) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
BioArctic AB 5-Year Yield-on-Cost % Related Terms
BRCTF vs VRTX, REGN, ALNY: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, BioArctic AB's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioArctic AB 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioArctic AB's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where BioArctic AB's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of BioArctic AB is calculated as
BioArctic AB (BRCTF) has a 5-Year Yield-on-Cost % of 0.67 as of Jul. 26, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on BioArctic AB and its competitors. This is 68% below median its historical median of 2.10. Over the past decade, BioArctic AB's 5-Year Yield-on-Cost % has ranged from 0.67 to 2.91. According to the industry distribution chart, BioArctic AB ranks #117 out of 150 companies in the Biotechnology industry, placing it in the top 78%.
Is BioArctic AB's 5-Year Yield-on-Cost % too high?
BioArctic AB's current 5-Year Yield-on-Cost % of 0.67 is 68% below median its 10-year median of 2.10. Over the past 10 years, this metric has ranged from a low of 0.67 to a high of 2.91. The Biotechnology industry median 5-Year Yield-on-Cost % is 1.70. BioArctic AB's value of 0.67 is 60.5% below this industry median. Based on the distribution chart, BioArctic AB ranks #117 out of 150 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioArctic AB has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioArctic AB's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioArctic AB ranks #117 out of 150 companies for 5-Year Yield-on-Cost %. This places BioArctic AB in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.70. BioArctic AB's value of 0.67 is 60.5% below this benchmark. Historically, BioArctic AB's own 5-Year Yield-on-Cost % has ranged from 0.67 to 2.91 over the past decade. While the company's 10-year median is 2.10 vs. the industry median of 1.70, BioArctic AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.70, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioArctic AB's current 5-Year Yield-on-Cost % of 0.67 is 60.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on BioArctic AB and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioArctic AB's current 5-Year Yield-on-Cost % is 0.67, which is 68% below median its own 10-year median of 2.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioArctic AB stock overvalued right now?
Based on GuruFocus' analysis, BioArctic AB (BRCTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $49.29, compared to a current price of $31.78 — trading 35.5% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.67, which is 68% below median its 10-year median of 2.10 and 60.5% below the Biotechnology industry median of 1.70. BioArctic AB's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For BioArctic AB (BRCTF), the current 5-Year Yield-on-Cost % is 0.67 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioArctic AB (BRCTF) Overvalued in 2026?
Based on GuruFocus' analysis, BioArctic AB stock appears to be undervalued.
The current stock price of $31.78 is trading 35.5% below its estimated GF Value™ of $49.29.
GuruFocus considers BioArctic AB to be Significantly Undervalued.
Key valuation signals for BRCTF:
5-Year Yield-on-Cost %: 0.67 (68% below median its 10-year median of 2.10)
GF Value™: $49.29 vs. price of $31.78 (35.5% below fair value)
Industry Position: 60.5% below the Biotechnology median (#117 of 150)
No single metric tells the full story. See the BRCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. Geographically, it derives a majority of its revenue from North America.
80GF Score
Get the complete analysis for BRCTF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BRCTF has been successfully added to your 
